Natalizumab Significantly Improves Cognitive Impairment over Three Years in MS: Pattern of Disability Progression and Preliminary MRI Findings.
Previous studies reported that Multiple Sclerosis (MS) patients treated with natalizumab for one or two years exhibit a significant reduction in relapse rate and in cognitive impairment, but the long term effects on cognitive performance are unknown. This study aimed to evaluate the effects of natal...
Main Authors: | Flavia Mattioli, Chiara Stampatori, Fabio Bellomi, Cristina Scarpazza, Ruggero Capra |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2015-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC4492934?pdf=render |
Similar Items
-
Natalizumab-Related Progressive Multifocal Leukoencephalopathy in Multiple Sclerosis: Findings from an Italian Independent Registry.
by: Luca Prosperini, et al.
Published: (2016-01-01) -
Divergent Trends of Anti-JCPyV Serum Reactivity and Neutralizing Activity in Multiple Sclerosis (MS) Patients during Treatment with Natalizumab
by: Roberta Antonia Diotti, et al.
Published: (2016-05-01) -
Immunological markers for PML prediction in MS patients treated with natalizumab
by: Caroline eAntoniol, et al.
Published: (2015-01-01) -
Significance of MRI Perivascular Spaces in MS
by: J Gordon Millichap
Published: (2008-10-01) -
New Algorithms Improving PML Risk Stratification in MS Patients Treated With Natalizumab
by: Inmaculada Toboso, et al.
Published: (2020-12-01)